Stock MNPR MONOPAR THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq
Other stock markets
 21:30:00 15/05/2024 BST 		5-day change 1st Jan Change
0.5981 USD -8.13% Intraday chart for Monopar Therapeutics Inc. -20.25% +75.81%
05-09 Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-16 Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
AQ
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
GL
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
AQ
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
GL
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
AQ
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
GL
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
GL
"Unleashing a Medical Revolution: Transformative Breakthroughs in Diagnosis and Treatment" VTAK, ALDX, MNPR, INBS, SIEN
AQ
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
GL
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
AQ
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
GL
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
AQ
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GL
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNPR Stock
  4. News Monopar Therapeutics Inc.
  5. Press Releases